Norethindrone has 44 known drug interactions based on U.S. FDA drug labeling data. 12 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Barbiturates, Bosentan, Carbamazepine. Patients taking Norethindrone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 44
- Major
- 12
- Moderate
- 30
- Minor
- 2
Major (12)
- Norethindrone + Barbiturates— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
- Norethindrone + Bosentan— Bosentan decreases norethindrone exposure by average of 14%, with decreases up to 56% in individual subjects, reducing h…
- Norethindrone + Carbamazepine— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
- Norethindrone + Colesevelam Hydrochloride— Colesevelam may decrease norethindrone exposure when coadministered with oral contraceptives. In vivo studies demonstrat…
- Norethindrone + Felbamate— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
- Norethindrone + Griseofulvin— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
- Norethindrone + Oxcarbazepine— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
- Norethindrone + Phenylbutazone— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
- Norethindrone + Phenytoin— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
- Norethindrone + Rifampin— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
- Norethindrone + St. John'S Wort— May reduce contraceptive effectiveness and cause breakthrough bleeding by inducing hepatic enzymes and p-glycoprotein tr…
- Norethindrone + Topiramate— May reduce contraceptive effectiveness and result in unintended pregnancy or breakthrough bleeding by increasing metabol…
Moderate (30)
- Norethindrone + Amlodipine And Atorvastatin— Levels may be increased when co-administered with atorvastatin.
- Norethindrone + Amprenavir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Anti-Inhibitor Coagulant Complex— May significantly change plasma levels of norethindrone, affecting safety and efficacy of contraceptive. Individual prot…
- Norethindrone + Aprepitant— May decrease systemic concentrations of norethindrone and potentially diminish contraceptive effectiveness or increase b…
- Norethindrone + Atazanavir— Significant increase in systemic exposure of norethindrone may occur.
- Norethindrone + Atorvastatin Calcium— Oral contraceptive component; atorvastatin may increase norethindrone values.
- Norethindrone + Boceprevir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Colchicine Tablets 0.5 Mg— Component of oral contraceptives; can cause adverse events like diarrhea, nausea, abdominal pain when coadministered. Us…
- Norethindrone + Colesevelam— Colesevelam may decrease exposure of oral contraceptives containing ethinyl estradiol and norethindrone.
- Norethindrone + Cyclosporine— Systemic concentrations of cyclosporine may increase due to hormonal contraceptive effects on metabolism.
- Norethindrone + Darunavir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Efavirenz— May decrease systemic concentrations of norethindrone and potentially diminish contraceptive effectiveness or increase b…
- Norethindrone + Etravirine— Significant increase in systemic exposure of norethindrone may occur.
- Norethindrone + Fluconazole— Substances increasing the systemic concentrations of HCs: Co-administration of certain HCs and strong or moderate CYP3A4…
- Norethindrone + Fosamprenavir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Grapefruit Juice— May increase systemic concentrations of norethindrone.
- Norethindrone + Indinavir— Significant increase in systemic exposure of norethindrone may occur.
- Norethindrone + Itraconazole— Substances increasing the systemic concentrations of HCs: Co-administration of certain HCs and strong or moderate CYP3A4…
- Norethindrone + Ketoconazole— Substances increasing the systemic concentrations of HCs: Co-administration of certain HCs and strong or moderate CYP3A4…
- Norethindrone + Lopinavir— Significant decrease in systemic concentrations of norethindrone when combined with ritonavir; may reduce contraceptive …
- Norethindrone + Lopinavir And Ritonavir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Nelfinavir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Nevirapine— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Rifabutin— May decrease systemic concentrations of norethindrone and potentially diminish contraceptive effectiveness or increase b…
- Norethindrone + Ritonavir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Rufinamide— May decrease systemic concentrations of norethindrone and potentially diminish contraceptive effectiveness or increase b…
- Norethindrone + Telaprevir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Thalidomide— Norethindrone is a hormonal contraceptive component; unclear if concomitant use with thalidomide increases thromboemboli…
- Norethindrone + Tipranavir— Significant decrease in systemic concentrations of norethindrone may occur.
- Norethindrone + Voriconazole— Substances increasing the systemic concentrations of HCs: Co-administration of certain HCs and strong or moderate CYP3A4…
Minor (2)
- Norethindrone + Isotretinoin— Clinical trial showed no clinically relevant changes in pharmacokinetics or hormone levels at recommended isotretinoin d…
- Norethindrone + Tazarotene— Concomitant use of tazarotene did not affect the pharmacokinetics of norethindrone in a trial of 27 healthy female subje…